Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | The future of mpMRI-based biomarkers in enhancing ICI efficacy

Kinga Bernatowicz • 22 Oct 2023
ESMO 2023
General Antibodies Checkpoint Inhibitors

Kinga Bernatowicz, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, discusses the benefits of multiparametric MRI (mpMRI)-based biomarkers, which can stratify patients with solid tumors based on who will benefit more from immune checkpoint inhibitors (ICIs). More personalized treatment programs can subsequently be implemented and the non-invasive procedures can be carried out with existing equipment. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Kinga Bernatowicz

1:24
The advantages of multiparametric MRI in assessing IO response
Kinga Bernatowicz • 22 Oct 2023
0:38
The benefits of mpMRI over conventional MRI imaging in oncology
Kinga Bernatowicz • 22 Oct 2023

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals